福元医药：子公司水杨酸苯酚贴膏上市许可持有人变更为福元药业

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received approval from the National Medical Products Administration for its subsidiary Fuyuan Pharmaceutical Co., Ltd. to hold the marketing authorization for "Salicylic Acid Phenol Plaster," previously held by Xi'an Kanghua Pharmaceutical Co., Ltd. [1] Group 1: Company Developments - The approval allows Fuyuan Pharmaceutical to expand its product line, enhancing its market competitiveness [1] - The "Salicylic Acid Phenol Plaster" is primarily used for treating corns, with projected sales in China's three major terminal markets reaching approximately 68.92 million yuan in 2024 [1] Group 2: Market Impact - The transition of the marketing authorization to Fuyuan Pharmaceutical is expected to positively impact its market position and sales potential in the dermatological treatment segment [1]